President Trump makes a historical announcement that he will be slapping on Pharmaceutical Tarrifs by the end of the Month

Gee… I wonder what this will do for the Kodak Stock? 😀👍

Months ago, I talked about KODAK being one stock I have heavily studied…

- I’ve been watching it since 2020, when President Trump put forth the Defense Production Act, and made an announcement about Kodak producing pharmaceuticals. The goal was to repurpose Kodak’s chemical manufacturing facilities in Rochester, New York.

• As of late 2024, Kodak is now independently heavily investing tens of millions into a new lab and manufacturing facility at Eastman Business Park, New York, expected to open in 2025.

• Fast forward to today, Trump’s tariffs will target foreign pharmaceutical companies.

This positions Kodak to produce APIs and reagents domestically, placing them way ahead of the competition by planning this restructuring since 2020, with its facility already nearing completion today, unlike competitors who may need years to relocate or build U.S.-based operations.

• Tariffs will likely raise costs for foreign-made APIs, making Kodak’s domestic production more competitive and potentially boosting demand… and its stock.

• Also, with potential short term drug shortages looming due to tariffs, Kodak’s soon established U.S.-based supply could see emergency demand spikes.

• Kodak’s stock historically surged (e.g., 300% in 2020 after the loan news)…

*Disclaimer… this isn’t financial advice. This is my own research for educational purposes.